Drug Trial Radar · NCT00650039
Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction
Last checked: Nov 20, 2026Latest source record: Jun 4, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
488
Actual
Start
Mar 2004
Primary completion
Not stated
Study completion Feb 2005
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 1, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective was to evaluate the analgesic efficacy of valdecoxib 20 mg daily and valdecoxib 20 mg twice daily compared with placebo in outpatients with moderate-severe pain after arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. Secondary objectives were to compare each valdecoxib dose with placebo on additional measures of pain intensity, health outcomes, the use of rescue medication, and the occurrence of opioid-related symptoms, and to evaluate their safety.
Conditions
- Pain
Interventions
placeboDrug
valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
valdecoxibDrug
valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
valdecoxibDrug
valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Summed Pain Intensity (categorical) through 24 hours (SPI 24)Time frame: Day 2 and Day 3
- Patient's Global Evaluation of Study Medication (PGESM)Time frame: Day 2 and Day 3
Locations
81 sites in 2 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Northport, Alabama
Pfizer Investigational Site
Glendale, Arizona
Pfizer Investigational Site
Pheonix, Arizona
Pfizer Investigational Site
Pheonix, Arizona
Pfizer Investigational Site
Pheonix, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Tempe, Arizona
Pfizer Investigational Site
Glendale, California
Pfizer Investigational Site
Laguna Hills, California
Pfizer Investigational Site
Laguna Woods, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Avon, Connecticut
Pfizer Investigational Site
Cromwell, Connecticut
Pfizer Investigational Site
Enfield, Connecticut
Pfizer Investigational Site
Farmington, Connecticut
Pfizer Investigational Site
Farmington, Connecticut
Pfizer Investigational Site
Glastonbury, Connecticut
Pfizer Investigational Site
Hartford, Connecticut
Pfizer Investigational Site
Hartford, Connecticut
Pfizer Investigational Site
Rocky Hill, Connecticut
Pfizer Investigational Site
Windsor, Connecticut
Pfizer Investigational Site
Hollywood, Florida
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Plantation, Florida
Pfizer Investigational Site
Saint Augustine, Florida
Pfizer Investigational Site
St. Petersburg, Florida
Pfizer Investigational Site
Weston, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Morrow, Georgia
Pfizer Investigational Site
Stockbridge, Georgia
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Oak Park, Illinois
Pfizer Investigational Site
Cedar Rapids, Iowa
Pfizer Investigational Site
Lexington, Kentucky
Pfizer Investigational Site
Lexington, Kentucky
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.